COVID-19 疫苗接种与葡萄膜炎：流行病学、临床特征和视觉预后。
COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis.
机构信息
Department of Ophthalmology, University Eye Hospital, Tuebingen, Germany.
Ocular Immunovirology Service, Department of Sense Organs, Sapienza University of Rome, Rome, Italy.
出版信息
Ocul Immunol Inflamm. 2022 Jul;30(5):1265-1273. doi: 10.1080/09273948.2022.2058964. Epub 2022 Apr 11.
PURPOSE
To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination.
PATIENTS AND METHODS
Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services.
RESULTS
In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p < .01).
CONCLUSION
COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.
目的
研究 COVID-19 疫苗接种后葡萄膜炎的流行病学和临床特征。
患者和方法
回顾性分析在三级葡萄膜炎专科就诊的 COVID-19 疫苗接种后出现葡萄膜炎的患者的病历。
结果
共纳入 25 名患者（76%为女性），平均年龄 43.2 岁。葡萄膜炎发生在接种辉瑞、莫德纳、阿斯利康和 Covaxin 疫苗之后。前葡萄膜炎是最常见的葡萄膜炎类型（56%）。19 例（76%）患者有葡萄膜炎病史，其中 90.9%的患者在接种疫苗后产生了抗 SARS-CoV-2 刺突抗体。在平均 5 个月的随访中，12%的患者视力出现了一线下降。在疫苗接种后葡萄膜炎期间，15.8%的病例需要增加全身治疗。根据 Naranjo 评分，新发葡萄膜炎与疫苗接种的相关性更高（p <.01）。
结论
COVID-19 疫苗接种可引起葡萄膜炎，但在病情缓解后对视力预后无显著影响。
Zotero 插件